Related Experiment Videos
Postmenopausal oestrogens and arteries
Insights
Postmenopausal estrogen therapy significantly reduces cardiovascular risks and bone loss, offering substantial health benefits for women. Routine HRT is recommended, especially for those without a uterus, pending further research on combined therapies.
Area of Science:
- Reproductive Endocrinology
- Cardiovascular Health
- Gerontology
Background:
- Postmenopausal estrogen therapy is linked to reduced cardiovascular morbidity and mortality.
- Epidemiological data suggest compelling evidence, supported by biologically plausible mechanisms.
- Hormone replacement therapy (HRT) also alleviates climacteric symptoms and preserves bone density.
Purpose of the Study:
- To evaluate the benefits and risks of postmenopausal estrogen therapy.
- To assess the routine offering of unopposed estrogen for postmenopausal women post-hysterectomy.
- To address the urgent need for data on cardiovascular protection with opposed HRT.
Main Methods:
- Review of epidemiological data and biologically plausible mechanisms.
- Consideration of consensus conference findings (Lobo & Speroff 1994).
- Analysis of benefits versus potential risks for different groups of women.
Main Results:
- Unopposed estrogen therapy is recommended routinely for postmenopausal women without a uterus.
- Women with a uterus require estrogen with cyclical progestogens; cardiovascular effects need urgent study.
- Estrogen's role in primary cardiovascular disease prevention is considered to outweigh potential risks for most women.
Conclusions:
- Postmenopausal estrogen therapy offers significant cardiovascular and bone health benefits.
- Routine HRT should be considered for postmenopausal women, with specific recommendations based on uterine status.
- Further research is crucial to clarify risks and benefits of opposed HRT for cardiovascular protection.
Abstract:
Postmenopausal oestrogen use is associated with a significant reduction in cardiovascular morbidity and mortality. The fact that a large scale controlled trial has not been conducted is a valid criticism, but the epidemiological data are compelling and there is evidence of biologically plausible mechanisms which may mediate this effect. Postmenopausal HRT also abolishes climacteric symptoms and conserves bone. For the postmenopausal woman who has had a hysterectomy, unless there are compelling reasons to the contrary, we believe that unopposed oestrogen therapy should be offered routinely. Women who still have a uterus (and these form the majority of potential HRT users) require oestrogens with cyclical progestogens. Whether such opposed therapy results in any reduction in cardiovascular protection needs to be addressed urgently. Meanwhile, it could be argued that these women should also be offered HRT routinely. Indeed, a recent consensus conference (Lobo & Speroff 1994) concluded that because of the magnitude of cardiovascular disease as a cause of morbidity and mortality, the beneficial role of estrogen in the primary prevention of cardiovascular disease in most women outweighs its potential risk. At the present time, there are insufficient data to indicate whether there are any groups of women for whom the risks may be too great to prescribe some form of estrogen therapy. As life expectancy increases in developed countries, such reductions in the leading cause of mortality are likely to benefit not only the individual woman, but the society in which she lives.